Ting-Yuan Lan

Dr. Ting-Yuan Lan

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 May 2023 in Hepatology International
Verified
Journal Article
Closed access
PDF file
SHShang-Chin Huang
Shang-Chin Huang
TSTung-Hung Su
Tung-Hung Su
TTTai-Chung Tseng
Tai-Chung Tseng
CCChi-An Chen
Chi-An Chen
SHShih-Jer Hsu
Shih-Jer Hsu
JKJia-Horng Kao
Jia-Horng Kao

26 June 2024 in American Journal of Gastroenterology
Verified
Journal Article
Closed access
SHShang-Chin Huang
Shang-Chin Huang
TSTung-Hung Su
Tung-Hung Su
TTTai-Chung Tseng
Tai-Chung Tseng
SLSih-Han Liao
Sih-Han Liao
SHShih-Jer Hsu
Shih-Jer Hsu
JKJia-Horng Kao
Jia-Horng Kao
INTRODUCTION: The prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) is increasing among the chronic hepatitis B (CHB) population. This study aimed to explore the impact of metabolic dysfunction (MD) on cirrhosis and cirrhotic complication risks in CHB. METHODS: Patients with CHB were consecutively recruited between 2006 and 2021. The presence of MD was based on the 5 cardiometabolic criteria specified in the MASLD definition. Patients were categorized into MD/non-MD groups based on these criteria. RESULTS: Eleven thousand five hundred two treatment-naive noncirrhotic patients with CHB were included with a median follow-up of 5.3 years. Patients in the MD group (n = 7,314) were older and had lower hepatitis B virus DNA levels than non-MD patients (n = 4,188). After adjustment for clinical and viral factors, MD patients had significantly higher risks of cirrhosis (adjusted hazard ratio [aHR]: 1.82, 95% confidence interval [CI]: 1.40–2.37, P < 0.001) and cirrhotic complications (aHR: 1.30 per MD, 95% CI: 1.03–1.63, P = 0.025) in a dose-dependent manner. Furthermore, new-onset diabetes mellitus during the follow-up aggravated the risk of cirrhotic complications (aHR: 2.87, 95% CI: 1.34–6.11, P = 0.006). Hepatic steatosis was associated with lower risks of cirrhosis (aHR: 0.57 within 5 years, 95% CI: 0.44–0.74, P < 0.001) and cirrhotic complications (aHR: 0.45, 95% CI 0.23–0.88, P = 0.020). Among individuals with hepatic steatosis, patients with MASLD exhibited a higher cirrhosis risk than non-MD patients. DISCUSSION: Concurrent and new-onset MDs increase the risks of cirrhosis and cirrhotic complications in patients with CHB, independent of hepatic steatosis. Proactively investigating metabolic comorbidities in CHB is critical to stratify the risk of liver disease progression.

21 October 2022 in Gut and Liver
Verified
Journal Article
Open access
PDF file
TLTing-Yuan Lan
Ting-Yuan Lan
YLYen-Chun Lin
Yen-Chun Lin
TTTai-Chung Tseng
Tai-Chung Tseng
HYHung-Chih Yang
Hung-Chih Yang
JKJui-Hung Kao
Jui-Hung Kao
SHSong-Chou Hsieh
Song-Chou Hsieh
Ting-Yuan Lan, Yen-Chun Lin, Tai-Chung Tseng, Hung-Chih Yang, Jui-Hung Kao, Chiao-Feng Cheng, Tai-Ju Lee, Shang-Chin Huang, Cheng-Hsun Lu, Ko-Jen Li, and Song-Chou Hsieh. Gut and Liver 2023;17:288-98. https://doi.org/10.5009/gnl210551

1 September 2021 in Diagnostics
Verified
Journal Article
Open access
PDF file
CCChiao-Feng Cheng
Chiao-Feng Cheng
MSMing-Chieh Shih
Ming-Chieh Shih
TLTing-Yuan Lan
Ting-Yuan Lan
KLKo-Jen Li
Ko-Jen Li
Anti-DFS70 antibodies have been proposed as a marker to exclude systemic autoimmune rheumatic disease (SARD). We conducted this systematic diagnostic test accuracy review and meta-analysis to determine the performance of anti-DFS70 antibodies in patients with a positive anti-nuclear antibody (ANA) test result to exclude SARD. We searched PubMed, Embase, Web of Science, Scopus and the Cochrane Library up to 22 February 2021, and included studies examining the diagnostic accuracy of anti-DFS70 antibodies in patients with a positive ANA test result. The results were pooled using a hierarchical bivariate model and plotted in summary receiver operating characteristic curves. R software and Stata Statistical Software were used for the statistical analysis. Eight studies with 4168 patients were included. The summary sensitivity was 0.19 (95% confidence interval: 0.12–0.28) and the specificity was 0.93 (95% confidence interval: 0.88–0.96). The area under the curve was 0.69 (95% confidence interval: 0.64–0.72). The meta-regression analysis showed that targeting only ANA-associated rheumatic disease was associated with higher specificity. In addition, the studies with a non-SARD prevalence of <80% and using a chemiluminescence assay were associated with higher specificity. Anti-DFS70 antibodies have high specificity for the exclusion of SARD among patients presenting with a positive ANA test, but the sensitivity is low.

29 July 2021 in Lupus
Verified
Journal Article
Closed access
PDF file
TLTing-Yuan Lan
Ting-Yuan Lan
YCYan-Siou Chen
Yan-Siou Chen
CCChiao-Feng Cheng
Chiao-Feng Cheng
SHSin-Tuan Huang
Sin-Tuan Huang
CSChieh-Yu Shen
Chieh-Yu Shen
PHPing-Ning Hsu
Ping-Ning Hsu
Progressive multifocal leukoencephalopathy (PML) is one of the rare but lethal infectious complication in patients with SLE, manifesting progressive central nervous demyelination caused by JC virus (JCV). There have been no effective antiviral agents so far; however, immune checkpoint inhibitors (ICI) have been demonstrated as potential treatments by reinvigorating antiviral T-cell activity against JC virus. To date, sixteen PML cases treated with anti-PD-1 have been reported; however, there was no report addressing the use of ICI in patients with concomitant PML and rheumatic disease, possibly due to the concern for possible autoimmune disease flare-up. In addition, treatment outcomes of these ICI-treated cases were heterogeneous. Experiences from these cases suggested that high disease burden, JC viral load in CSF, and severe immunosuppression status at baseline may predict poor response to treatment. Our case, a 62-year-old woman with long-standing SLE, turned out to have a delayed but effective response to prolonged ICI treatment despite of her high JC viral load and immunosuppressed status caused by high-dose steroid and rituximab. To our knowledge, this is the first case report with SLE complicated with PML clinically improved by pembrolizumab treatment without consequent immune related adverse events (irAE). Considering the lethal nature of PML and absence of effective medication, ICI is a reasonable consideration in patients with SLE and progressive PML.

6 August 2025 in Rheumatology
Verified
Journal Article
Closed access
TLTing-Yuan Lan
Ting-Yuan Lan
TLTai-Ju Lee
Tai-Ju Lee
TCTing-Wei Chang
Ting-Wei Chang
TTTai-Chung Tseng
Tai-Chung Tseng
PLPei-Hsinq Lai
Pei-Hsinq Lai
KLKo-Jen Li
Ko-Jen Li
Objective: HBV reactivation is a critical concern for patients with autoimmune disease undergoing immunosuppressive therapy. Despite data on HBV reactivation risks associated with biologics, the impact of the new targeted immunosuppressive agents—Janus kinase inhibitors (JAKis)—remains unclear. This study aimed to evaluate the risk of HBV reactivation among patients with RA treated with JAKis, compared with those receiving TNF inhibitors (TNFis) or rituximab. Method: We conducted a retrospective analysis of patients with RA treated at the National Taiwan University Hospital from 2015 to 2023. Patients with available baseline HBV status [HBsAg, hepatitis B core antibody (anti-HBc), hepatitis B surface antibody (anti-HBs), HBV DNA] who received TNFis, rituximab, or JAKis (tofacitinib, baricitinib, upadacitinib) were included. The primary outcomes were hepatitis flare in HBsAg-positive patients and HBsAg seroreversion in HBsAg-negative/anti-HBc–positive patients. Results: We included 35 HBsAg-positive patients and 339 patients with resolved HBV infection (HBsAg-negative/anti-HBc–positive). Among those with resolved HBV infection, the reactivation risk was low with TNFis (0.9%, 2.8/1000 person-years), and higher with rituximab (3.2%, 15.1/1000 person-years) and JAKis overall (2.9%, 10.3/1000 person-years). Among individual JAKis, upadacitinib had the highest incidence (6.5%, 42.8/1000 person-years), followed by baricitinib (4.7%, 19.2/1000 person-years), and tofacitinib (1.0%, 2.7/1000 person-years). Among HBsAg-positive patients, 50% of JAKi users developed a hepatitis flare, emphasizing the importance of vigilant monitoring and prophylaxis. Conclusion: Our findings reveal a non-negligible risk of HBV reactivation among RA patients receiving JAKi therapy, particularly with the more JAK1-selective JAKis. Larger registry or prospective studies are needed to validate these findings.